BLPH Bellerophon Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

BLPH [NASD]

Bellerophon Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.82	Insider Own	1.60%	Shs Outstand	4.62M	Perf Week	-5.60%
Market Cap	119.01M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	0.00%	Shs Float	4.41M	Perf Month	-21.35%
Income	-17.40M	PEG	-	EPS next Q	-0.72	Inst Own	16.10%	Short Float	2.85%	Perf Quarter	58.24%
Sales	-	P/S	-	EPS this Y	-554.00%	Inst Trans	-22.00%	Short Ratio	0.21	Perf Half Y	119.22%
Book/sh	0.47	P/B	27.98	EPS next Y	34.20%	ROA	-112.80%	Target Price	-	Perf Year	45.89%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-284.20%	52W Range	3.19 - 26.00	Perf YTD	150.69%
Dividend	-	P/FCF	-	EPS past 5Y	47.70%	ROI	-	52W High	-49.42%	Beta	-0.73
Dividend %	-	Quick Ratio	1.30	Sales past 5Y	-	Gross Margin	-	52W Low	312.76%	ATR	1.35
Employees	18	Current Ratio	1.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.40	Volatility	7.00% 8.87%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-488.80%	Profit Margin	-	Rel Volume	0.68	Prev Close	13.77
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	588.30K	Price	13.15
Recom	2.00	SMA20	-15.33%	SMA50	-6.59%	SMA200	53.58%	Volume	402,253	Change	-4.50%

Jan-24-19

Initiated

Maxim Group

Buy

Apr-17-17

Initiated

Ladenburg Thalmann

Buy

$4.50

Jan-20-17

Initiated

H.C. Wainwright

Buy

Mar-22-16

Reiterated

Leerink Partners

Outperform

$11 → $9

Jul-27-15

Reiterated

FBR Capital

Outperform

$23 → $11

Mar-16-15

Initiated

FBR Capital

Outperform

$23

Jun-04-20 06:42PM	Is Bellerophon Therapeutics, Inc. (BLPH) A Good Stock To Buy? Insider Monkey
May-29-20 03:40PM	Alan Fournier Adds 4 Stocks to Portfolio GuruFocus.com
May-22-20 09:47AM	Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire +7.99%
May-19-20 06:53PM	8 Biotechs Tapping Secondary Markets for $3 Billion GuruFocus.com -19.55%
07:00AM	Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering GlobeNewswire
May-18-20 04:03PM	Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
May-12-20 10:09AM	Company News for May 12, 2020 Zacks -6.02%
May-11-20 04:01PM	Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results GlobeNewswire +19.22%
08:30AM	Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19 GlobeNewswire
May-04-20 08:30AM	Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Groups Infectious Disease Virtual Conference GlobeNewswire
Apr-17-20 12:19PM	These experimental drugs may help keep COVID-19 patients off ventilators MarketWatch
Apr-08-20 08:23PM	Covid-19: Could Bellerphon Therapeutics INOpulse Help Address Hospital Ventilator Shortage? SmarterAnalyst -8.87%
08:30AM	Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 GlobeNewswire
Apr-06-20 10:23AM	Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Apr-01-20 01:06PM	Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock GlobeNewswire -13.96%
Mar-31-20 08:30AM	Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19 GlobeNewswire -10.89%
Mar-30-20 09:57AM	Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
08:00AM	Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19 GlobeNewswire
Mar-29-20 03:44PM	Bellerophon Shares Jump On Covid-19 OK GuruFocus.com
Mar-23-20 09:30AM	Company News for Mar 23, 2020 Zacks -32.67%
Mar-22-20 08:19AM	3 Coronavirus Stocks with Over 60% Upside TipRanks
Mar-20-20 08:30AM	FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus GlobeNewswire +430.97%
Mar-10-20 08:30AM	Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis GlobeNewswire -5.91%
Feb-21-20 12:11PM	The One Metric That Helps Me Find Stocks With The Greatest Potential Benzinga
Feb-19-20 10:32AM	Company News for Feb 19, 2020 Zacks -11.90%
09:21AM	Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
07:21AM	The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga
Feb-18-20 08:30AM	Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis GlobeNewswire +168.37%
Feb-07-20 12:00PM	Bellerophon Announces 1-for-15 Reverse Stock Split GlobeNewswire -18.75%
Dec-20-19 04:18PM	Is Bellerophon Therapeutics, Inc. (BLPH) Going to Burn These Hedge Funds? Insider Monkey
Dec-17-19 08:44AM	Bellerophon stock is up 35% on hypertension trial data MarketWatch -10.82%
07:00AM	Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-12-19 08:30AM	Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-07-19 08:30AM	Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019 GlobeNewswire
Nov-06-19 08:30AM	Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-01-19 11:51AM	Largest Insider Trades of the Week GuruFocus.com
Oct-28-19 07:15AM	BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow Zacks Small Cap Research -15.89%
Oct-23-19 08:30AM	Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting GlobeNewswire
07:54AM	The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-20-19 08:08AM	The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-14-19 08:30AM	Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting GlobeNewswire
Sep-16-19 08:30AM	Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-04-19 08:30AM	Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-08-19 12:57PM	Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Insiders Increased Their Holdings Simply Wall St.
08:30AM	Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 08:15PM	BLPH: Zacks SCR Initiates Coverage of Bellerophon Therapeutics Zacks Small Cap Research
Aug-01-19 08:30AM	Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Jun-13-19 08:00AM	Bellerophon to Present at the JMP Securities Life Sciences Conference GlobeNewswire
May-22-19 08:30AM	Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
May-21-19 08:30AM	Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference GlobeNewswire
May-18-19 09:50AM	The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-13-19 08:30AM	Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference GlobeNewswire
May-09-19 08:45AM	Bellerophon Therapeutics: 1Q Earnings Snapshot Associated Press
08:30AM	Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-03-19 12:10PM	What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)? Simply Wall St.
Apr-08-19 08:30AM	Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +7.53%
Mar-18-19 02:08PM	Did Changing Sentiment Drive Bellerophon Therapeuticss (NASDAQ:BLPH) Share Price Down A Painful 76%? Simply Wall St.
Mar-14-19 09:09AM	Bellerophon Therapeutics: 4Q Earnings Snapshot Associated Press
08:30AM	Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Jan-28-19 08:30AM	Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients GlobeNewswire
Jan-25-19 04:05PM	Bellerophon Announces Closing of $7 Million Public Offering of Common Stock GlobeNewswire
Jan-23-19 06:00AM	Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock GlobeNewswire -23.91%
Jan-22-19 04:44PM	Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -7.57%
Jan-07-19 08:30AM	Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +26.74%
Nov-21-18 08:55AM	Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-16-18 01:32AM	DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire
Nov-07-18 09:36AM	Bellerophon Therapeutics: 3Q Earnings Snapshot Associated Press +8.33%
08:30AM	Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-09-18 08:30AM	Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Sep-10-18 11:40AM	3 Biotech & Marijuana Stocks to Pay Attention to this Quarter ACCESSWIRE +28.18%
Aug-29-18 08:00AM	Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 08:00AM	Todays Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics ACCESSWIRE +10.75%
Aug-08-18 08:15AM	The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga -15.34%
Aug-07-18 08:30AM	Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire -68.86%
Aug-01-18 09:16AM	Bellerophon Therapeutics: 2Q Earnings Snapshot Associated Press
08:40AM	Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jun-15-18 09:13AM	5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks
Jun-12-18 08:39AM	The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp Zacks -6.00%
08:00AM	Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference GlobeNewswire
Jun-11-18 12:45PM	5 Top-Ranked Small Caps to Buy as Trade Tensions Escalate InvestorPlace
09:08AM	Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate Zacks
May-16-18 08:30AM	Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference GlobeNewswire
May-10-18 08:45AM	Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 08:30AM	Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire
Apr-30-18 08:43AM	Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher Zacks
Apr-19-18 09:35AM	3 Biotech Stocks That Will Thrive Amid Market Instability InvestorPlace +5.31%
Apr-03-18 08:30AM	Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-27-18 07:00AM	Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018 ACCESSWIRE
Mar-23-18 10:56AM	Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher? Zacks -8.39%
Mar-15-18 07:17PM	Bellerophon Therapeutics posts 4Q loss Associated Press
04:45PM	Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Jan-29-18 08:30AM	Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire
Jan-03-18 08:30AM	Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-30-17 05:46PM	Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors GlobeNewswire
Nov-07-17 08:43AM	Bellerophon Therapeutics posts 3Q loss Associated Press
08:30AM	Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Sep-27-17 08:30AM	Bellerophon Announces $23 Million Private Placement GlobeNewswire +18.52%
Sep-07-17 04:01PM	Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences GlobeNewswire
Sep-05-17 08:40AM	Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment MarketWatch
08:30AM	Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wang Theodore T	Director	Nov 25	Buy	0.39	7,193	2,774	592,922	Nov 25 04:52 PM
Wang Theodore T	Director	Nov 22	Buy	0.37	1,050	394	585,729	Nov 25 04:52 PM
Wang Theodore T	Director	Nov 21	Buy	0.37	200	74	584,679	Nov 25 04:52 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 28	Sale	0.44	333,010	146,091	6,435,173	Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 28	Sale	0.44	333,010	146,091	6,435,173	Oct 28 05:15 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 25	Sale	0.45	56,242	25,511	6,768,183	Oct 28 05:15 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 25	Sale	0.45	56,242	25,511	6,768,183	Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 24	Sale	0.50	704,595	353,354	6,824,425	Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P	10% Owner	Oct 24	Sale	0.50	704,595	353,354	6,824,425	Oct 28 05:15 PM
Wang Theodore T	Director	Jun 12	Buy	0.64	50,000	31,905	584,479	Jun 14 11:46 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience